Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update

Rhea-AI Summary

Ardelyx (ARDX) reported strong Q1 2025 financial results with total revenue of $74.1 million, representing 61% growth year-over-year. Key highlights include IBSRELA net product sales of $44.4 million (57% YoY growth) and XPHOZAH net product sales of $23.4 million. The company maintained a solid financial position with $214.0 million in cash and investments. IBSRELA's full-year 2025 revenue guidance remains between $240-250 million. Notable developments include tenapanor's approval in China for hyperphosphatemia, earning a $5.0 million milestone payment from Fosun Pharma. However, the company reported a net loss of $41.1 million ($0.17 per share) for Q1 2025, compared to $26.5 million loss in Q1 2024, primarily due to increased commercialization costs.

Positive

• Total revenue grew 61% year-over-year to $74.1 million in Q1 2025
• IBSRELA sales increased 57% YoY to $44.4 million
• XPHOZAH sales grew 30% YoY (excluding returns reserve release)
• Strong cash position of $214.0 million
• Received $5.0 million milestone payment for China approval of tenapanor

Negative

• Net loss increased to $41.1 million from $26.5 million YoY
• SG&A expenses increased significantly to $83.2 million from $53.0 million YoY
• R&D expenses increased to $14.9 million from $10.6 million YoY

Insights

Financial Analyst

Strong 61% revenue growth to $74.1M, but widening losses as Ardelyx scales operations; cash position solid at $214M despite increasing expenses.

Ardelyx's Q1 2025 results demonstrate impressive commercial momentum with total revenue reaching $74.1 million, a 61% year-over-year increase. The company's dual product portfolio is performing exceptionally well, with IBSRELA generating $44.4 million in net sales (57% YoY growth) and XPHOZAH contributing $23.4 million, including a $3.8 million release from prior period returns reserves.

While gross margins remain healthy, operating expenses climbed significantly to $98.2 million versus $63.6 million in Q1 2024. The company specifically attributes this increase to commercialization costs for both key products. This elevated spending resulted in a widened net loss of $41.1 million ($0.17 per share) compared to $26.5 million ($0.11 per share) in the prior year period.

The cash position declined from $250.1 million at year-end 2024 to $214.0 million, reflecting the substantial investments in commercial infrastructure. However, this represents a reasonable burn rate given the revenue acceleration, providing sufficient runway for continued execution of the company's stated priorities.

Management's full-year 2025 guidance for IBSRELA of $240-250 million suggests confidence in maintaining strong growth momentum. The $5 million milestone payment from Fosun Pharma following tenapanor's approval in China demonstrates the potential value of Ardelyx's international partnering strategy, though this currently represents a small portion of overall revenue.

The financial results indicate Ardelyx is in a high-growth scaling phase, prioritizing commercial expansion over near-term profitability – a typical approach for commercial-stage biotech companies with novel products gaining market traction.

Pharmaceutical Industry Specialist

Ardelyx's dual product strategy shows strong commercial success with 57% growth for IBSRELA and solid XPHOZAH performance despite market challenges.

Ardelyx has delivered exceptional commercial progress in Q1 2025, particularly impressive for a specialty pharmaceutical company with two first-in-class therapies. IBSRELA's 57% year-over-year growth is striking for a product in its third commercial year, indicating it continues to meet significant unmet needs in IBS-C (Irritable Bowel Syndrome with Constipation). The product's momentum suggests physicians and patients are increasingly recognizing its value proposition as a novel sodium/hydrogen exchanger 3 (NHE3) inhibitor.

XPHOZAH's performance is equally noteworthy, especially considering the "ongoing disruption in the dialysis community" mentioned in the release. The $3.8 million release of returns reserves reflects growing confidence in the product's durability based on actual returns history, suggesting improving market acceptance and integration into treatment protocols for hyperphosphatemia in dialysis patients.

The Chinese approval for tenapanor represents an important milestone in Ardelyx's global commercialization strategy. This expansion not only generated an immediate $5 million milestone payment but also positions the company to address hyperphosphatemia in the world's largest potential patient population through the Fosun Pharma partnership.

The strategic leadership additions of Dr. Merdad Parsey to the Board and Dr. Laura Williams as Chief Patient Officer signal Ardelyx's commitment to both scientific excellence and patient-centered commercial strategies. The increased R&D spending ($14.9 million vs. $10.6 million in Q1 2024) indicates investment in scientific engagement, which is critical for specialty products that require education around novel mechanisms of action.

The company's stated focus on "accelerating commercial growth for IBSRELA, deepening the adoption and impact of XPHOZAH, building a pipeline of innovative therapies, and maintaining disciplined financial performance" aligns with an appropriate strategy for a commercial-stage biotech with high-potential, differentiated products in specialty markets.

Company reports $74.1 million in Q1 total revenue, reflecting 61% growth year-over-year

IBSRELA net product sales revenue of $44.4 million; XPHOZAH net product sales revenue of $23.4 million 

Company ends Q1 with $214.0 million in cash, cash equivalents and investments

Conference call scheduled for 4:30 PM Eastern Time

WALTHAM, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2025 and provided a business update.

“Ardelyx delivered an outstanding first quarter, generating $74 million in total revenue and advancing our key strategic priorities,” said Mike Raab, president and chief executive officer of Ardelyx. “As IBSRELA enters its third full year on the market, it achieved exceptional year-over-year growth of 57%, a testament to the significant clinical value it delivers and the strength of our commercial strategy. XPHOZAH also posted strong year-over-year growth, despite ongoing disruption in the dialysis community, underscoring the high unmet need among patients and the momentum built by the team in 2024. The results affirm our confidence in XPHOZAH’s long-term potential and the important and expanding impact on care for patients with chronic kidney disease on dialysis. Importantly, we continued to thoughtfully manage our operating expenses, preserving a strong balance sheet, and positioned the company for success and value creation as we execute on our mission to improve the lives of patients with serious diseases.”

Raab continued, “Looking ahead to the next quarter and the remainder of 2025, we remain sharply focused on the strategic priorities fueling our momentum: accelerating commercial growth for IBSRELA, deepening the adoption and impact of XPHOZAH, building a pipeline of innovative therapies, and maintaining a disciplined financial performance. We are confident in our ability to continue delivering meaningful results for patients, healthcare providers and shareholders.”

IBSRELA^® (tenapanor) records $44.4 million in net product sales revenue in Q1 2025
U.S. net product sales revenue for IBSRELA during the first quarter of 2025 was $44.4 million, reflecting significant year-over-year growth of approximately 57%. The strong growth was driven by increases across key demand indicators, including total writers and new and refill prescriptions.

Ardelyx continues to expect full-year 2025 U.S. net product sales revenue for IBSRELA to be between $240.0 and $250.0 million.

XPHOZAH^® (tenapanor) records $23.4 million net product sales revenue during Q1 2025
U.S. net product sales revenue for XPHOZAH during the first quarter of 2025 was $23.4 million, driven by strong commercial momentum and execution. Net sales revenue during this period reflects the release of $3.8 million of prior periods’ estimated product returns for XPHOZAH, based on assumptions from actual returns history and other data supporting an expectation of minimal returns. Excluding the returns reserve release, net sales revenue for XPHOZAH grew 30% compared to the first quarter of 2024.

Other Corporate Developments

• In April, the company announced the appointment of Merdad Parsey, M.D. Ph.D., to its Board of Directors
• In April, the company announced the appointment of Laura A. Williams, M.D., M.P.H., as the company’s first Chief Patient Officer.
• In February, the company announced the approval of tenapanor in China for hyperphosphatemia. Ardelyx earned a $5.0 million milestone payment from Fosun Pharma following the approval.
  

First Quarter 2025 Financial Results

• Cash Position: As of March 31, 2025, the company had total cash, cash equivalents and short-term investments of $214.0 million, as compared to total cash, cash equivalents and short-term investments of $250.1 million as of December 31, 2024.
• Revenues: Total revenue for the quarter ended March 31, 2025 was $74.1 million, compared to $46.0 million in total revenue during the quarter ended March 31, 2024, reflecting increased net product sales and licensing revenue.

- IBSRELA U.S. net product sales revenue was $44.4 million, compared to $28.4 million during the same period of 2024.

- XPHOZAH U.S. net product sales revenue was $23.4 million, compared to $15.2 million during the same period of 2024.

- Product supply revenue was $0.3 million, compared to $2.1 million during the same period of 2024.

- Licensing revenue was $5.0 million, compared to $17 thousand during the same period of 2024. The increase is related to a $5.0 million milestone from Fosun Pharma following the approval of tenapanor for hyperphosphatemia in China.

- Non-cash royalty revenue related to the sale of future royalties was $1.0 million, compared to $0.4 million during the same period of 2024.

• R&D Expenses: Research and development expenses were $14.9 million for the quarter ended March 31, 2025, compared to $10.6 million for the quarter ended March 31, 2024. The increase was primarily related to increased engagement with the scientific and medical communities.
  
  
• SG&A Expenses: Selling, general and administrative expenses were $83.2 million for the quarter ended March 31, 2025, compared to $53.0 million for the quarter ended March 31, 2024. The increase was primarily related to increased costs associated with the ongoing commercialization of IBSRELA and XPHOZAH.
  
  
• Net Loss: Net loss for the quarter ended March 31, 2025 was $41.1 million, or $(0.17) per share, compared to net loss of $26.5 million, or $(0.11) per share, for the quarter ended March 31, 2024. The net loss for the first quarter of 2025 included share-based compensation expense of $12.1 million and non-cash interest expense related to the sale of future royalties of $2.1 million.

Conference Call Details
The company will host a conference call today, May 1, 2025, at 4:30 PM ET to discuss today’s announcement. To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. A webcast of the call can also be accessed by visiting the Investor page of the company's website, https://ardelyx.com/, and will be available on the website for 30 days following the call.

IMPORTANT SAFETY INFORMATION (IBSRELA)

WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS IBSRELA is contraindicated in patients less than 6 years of age; in nonclinical studies in young juvenile rats administration of tenapanor caused deaths presumed to be due to dehydration. Avoid use of IBSRELA in patients 6 years to less than 12 years of age. The safety and effectiveness of IBSRELA have not been established in patients less than 18 years of age.

CONTRAINDICATIONS

• IBSRELA is contraindicated in patients less than 6 years of age due to the risk of serious dehydration.
• IBSRELA is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.

WARNINGS AND PRECAUTIONS
Risk of Serious Dehydration in Pediatric Patients

• IBSRELA is contraindicated in patients below 6 years of age. The safety and effectiveness of IBSRELA in patients less than 18 years of age have not been established. In young juvenile rats (less than 1 week old; approximate human age equivalent of less than 2 years of age), decreased body weight and deaths occurred, presumed to be due to dehydration, following oral administration of tenapanor. There are no data available in older juvenile rats (human age equivalent 2 years to less than 12 years).
• Avoid the use of IBSRELA in patients 6 years to less than 12 years of age. Although there are no data in older juvenile rats, given the deaths in younger rats and the lack of clinical safety and efficacy data in pediatric patients, avoid the use of IBSRELA in patients 6 years to less than 12 years of age.

Diarrhea
Diarrhea was the most common adverse reaction in two randomized, double-blind, placebo-controlled trials of IBS-C. Severe diarrhea was reported in 2.5% of IBSRELA-treated patients. If severe diarrhea occurs, suspend dosing and rehydrate patient.

MOST COMMON ADVERSE REACTIONS
The most common adverse reactions in IBSRELA-treated patients (incidence ≥2% and greater than placebo) were: diarrhea (16% vs 4% placebo), abdominal distension (3% vs <1%), flatulence (3% vs 1%) and dizziness (2% vs <1%).

INDICATION
IBSRELA (tenapanor) is indicated for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adults.

Please see full Prescribing Information, including Boxed Warning, for additional risk information.

IMPORTANT SAFETY INFORMATION (XPHOZAH)

CONTRAINDICATIONS

XPHOZAH is contraindicated in:

• Pediatric patients under 6 years of age
• Patients with known or suspected mechanical gastrointestinal obstruction

WARNINGS AND PRECAUTIONS
Diarrhea
Patients may experience severe diarrhea. Treatment with XPHOZAH should be discontinued in patients who develop severe diarrhea.

MOST COMMON ADVERSE REACTIONS
Diarrhea, which occurred in 43-53% of patients, was the only adverse reaction reported in at least 5% of XPHOZAH-treated patients with CKD on dialysis across trials. The majority of diarrhea events in the XPHOZAH-treated patients were reported to be mild-to-moderate in severity and resolved over time, or with dose reduction. Diarrhea was typically reported soon after initiation but could occur at any time during treatment with XPHOZAH. Severe diarrhea was reported in 5% of XPHOZAH-treated patients in these trials.

INDICATION
XPHOZAH (tenapanor), 30 mg BID, is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

For additional safety information, please see full Prescribing Information.

About Ardelyx
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA^® (tenapanor) and XPHOZAH^® (tenapanor) as well as early-stage pipeline candidates. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL^® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.

Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995, including Ardelyx’s current expectations regarding: the long term potential for Ardelyx’s existing commercial products; opportunities for continued IBSRELA growth; opportunities for deepening the adoption and impact of XPHOZAH and the projected U.S. net product sales revenue for IBSRELA for full year 2025. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control, that could cause actual outcomes or results to differ materially from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties associated with the development of, regulatory process for, and commercialization of drugs in the U.S. and internationally. Ardelyx undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ardelyx's business in general, please refer to Ardelyx's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 1, 2025, and its future current and periodic reports to be filed with the Securities and Exchange Commission.

Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com

Ardelyx, Inc.
Condensed Balance Sheets
(in thousands)

	March 31, 2025			December 31, 2024
	(Unaudited)				(1	)
Assets
Cash and cash equivalents	$	30,808		$	64,932
Short-term investments		183,144			185,168
Accounts receivable		46,467			57,705
Prepaid commercial manufacturing		17,094			16,378
Inventory		105,875			91,184
Property and equipment, net		1,665			1,495
Right-of-use assets		3,670			2,380
Prepaid and other assets		21,471			16,512
Total assets	$	410,194		$	435,754
Liabilities and stockholders’ equity
Accounts payable	$	13,722		$	16,000
Accrued compensation and benefits		7,168			14,940
Current portion of operating lease liability		1,302			1,562
Deferred revenue		19,263			17,918
Accrued expenses and other liabilities		45,240			35,665
Long-term debt		151,301			150,853
Deferred royalty obligation related to the sale of future royalties		26,522			25,527
Total stockholders’ equity		145,676			173,289
Total liabilities and stockholders’ equity	$	410,194		$	435,754

_{⁽¹⁾ Derived from the audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024.}

Ardelyx, Inc.
Condensed Statements of Operations
(Unaudited)
(in thousands, except share and per share amounts)

	Three Months Ended March 31,
		2025				2024
Revenues
Product sales, net
IBSRELA	$	44,403			$	28,361
XPHOZAH		23,411				15,151
Total product sales, net		67,814				43,512
Product supply revenue		254				2,126
Licensing revenue		5,020				17
Non-cash royalty revenue related to the sale of future royalties		1,026				368
Total revenues		74,114				46,023
Cost of goods sold
Cost of product sales		2,340				1,013
Other cost of revenue		9,963				6,115
Total cost of goods sold		12,303				7,128
Operating expenses
Research and development		14,938				10,579
Selling, general and administrative		83,222				52,994
Total operating expenses		98,160				63,573
Loss from operations		(36,349	)			(24,678	)
Interest expense		(4,191	)			(2,356	)
Non-cash interest expense related to the sale of future royalties		(2,071	)			(1,702	)
Other income, net		2,326				2,339
Loss before provision for income taxes		(40,285	)			(26,397	)
Provision for income taxes		859				121
Net loss	$	(41,144	)		$	(26,518	)
Net loss per share of common stock - basic and diluted	$	(0.17	)		$	(0.11	)
Shares used in computing net loss per share - basic and diluted		238,624,145				233,065,960

FAQ

What were Ardelyx (ARDX) Q1 2025 earnings results?

Ardelyx reported Q1 2025 total revenue of $74.1 million (61% YoY growth), with IBSRELA sales of $44.4 million and XPHOZAH sales of $23.4 million. The company posted a net loss of $41.1 million ($0.17 per share).

What is Ardelyx (ARDX) revenue guidance for IBSRELA in 2025?

Ardelyx expects full-year 2025 U.S. net product sales revenue for IBSRELA to be between $240.0 and $250.0 million.

How much cash does Ardelyx (ARDX) have as of Q1 2025?

Ardelyx had $214.0 million in total cash, cash equivalents and short-term investments as of March 31, 2025.

What was XPHOZAH's sales performance in Q1 2025?

XPHOZAH generated $23.4 million in net product sales, including a $3.8 million release of prior periods' estimated returns. Excluding the returns reserve release, sales grew 30% compared to Q1 2024.

What recent developments occurred at Ardelyx (ARDX)?

In Q1 2025, Ardelyx received approval for tenapanor in China, earning a $5.0 million milestone payment. The company also appointed Merdad Parsey to its Board and Laura A. Williams as Chief Patient Officer.